Sodium hyaluronate combined with rhEGF contributes to alleviate clinical symptoms and Inflammation in patients with Xerophthalmia after cataract surgery

Abstract

Background To determine the effect of sodium hyaluronate combined with recombinant human epidermal growth factor (rhEGF) on clinical symptoms and inflammation in patients with newly diagnosed xerophthalmia after cataract surgery. Methods A total of 106 patients who underwent cataract surgery and were newly diagnosed with xerophthalmia in our hospital between June 2018 and August 2019 were enrolled. Of these, 50 patients who were treated with sodium hyaluronate (0.1%) were assigned to the monotherapy group (MG) and the remaining 56 patients who were treated with sodium hyaluronate (0.1%) combined with rhEGF (20 μg/ml) were assigned to the combination group (CG). The 2 groups were compared based on ocular surface disease index (OSDI) score, break-up time (BUT), fluorescein corneal staining level, Schirmer I test (SI) level, clinical efficacy (disappearance of typical symptoms, including eyes drying, burning sensation, foreign body sensation, etc), and interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α) levels. Spearman correlation analysis was conducted to analyze the relationship between IL-1, IL-6, TNF-α and clinical efficacy. In addition, receiver operating characteristic curves were drawn to analyze the predictive value of IL-1, IL-6, and TNF-α in efficacy on xerophthalmia. Results: After treatment, the CG showed reduced OSDI score compared with the MG. The CG showed increased BUT (s) and SI (mm) levels compared with MG. After treatment, the CG exhibited decreased levels of IL-1(ng/mL), IL-6 (ng/mL), and TNF-α (ng/mL) compared with the MG. Spearman correlation analysis revealed that IL-1, IL-6, and TNF-α were negatively correlated with clinical efficacy. The areas under the curves of IL-1, IL-6, and TNF-α were 0.801, 0.800, and 0.736 respectively. Conclusions Sodium hyaluronate combined with rhEGF is helpful to alleviate clinical symptoms and inflammation in patients with xerophthalmia undergoing cataract surgery.

Effects of Recombinant Human Epidermal Growth Factor Eye Drops Combined with Phacoemulsification on Short- and Long-Term Visual Acuity Recovery and Related Dry Eye Complications in Patients with Senile Cataract

“…Even at very low doses, benzalkonium bromide, the most commonly used eye preservative, can cause inflammation in corneal epithelial cells, using artificial tears without preservatives. At present, there are few reports on the combination of sodium hyaluronate and rEGF without preservatives, and the therapeutic effect of the combination of sodium hyaluronate and rEGF in the elderly population with dry eyes is rarely reported [30][31][32].…”

Sodium Hyaluronate Combined with Pranolprofen Improve Visual Function and Reduce Inflammation in Patients with Dry eye

“…Some studies have found that when ocular diseases develop, the levels of IL-1, IL-6 and other factors were memorably elevated, and high levels of in ammatory factors might interfere with ocular surface homeostasis. With the aggravation of the disease, the levels of in ammatory factors in patients gradually increased, and were closely related to the clinical symptoms [20][21] . This work showed that the joint treatment signally reduced in ammatory response and promoted the improvement of dry eye syndrome.…”

Efficacy of recombinant human epidermal growth factor plus sodium hyaluronate eye drops in diabetic dry eye post-cataract surgery

“…Therefore, the current treatment approach needs to be clinically addressed to make up for the shortcomings of these therapies[ 7 , 8 ]. Recombinant human epidermal growth factor (rhEGF), a multifunctional growth factor that promotes tear secretion and lacrimal gland cell proliferation, improves the regeneration ability of corneal epithelial cells and shortens the repair time of damaged corneal tissues, thereby promoting the functional recovery of corneal endothelial cells[ 9 ].…”